Quintiles To Support Chemosat Launch

Delcath Systems, Inc. has selected Quintiles to provide a specialized team of Medical Science Liaisons (MSLs) to support the launch of the Hepatic Chemosat Delivery system for the treatment of liver cancer in France, Germany, Italy, Netherlands, Spain, Ireland and the UK. Quintiles will also provide medical communication to support patient advocacy, key opinion leader development, and field force materials.

“This agreement gives us a highly professional medical science team in Europe with which we can begin communicating to and educating medical oncologists and liver specialists on the benefits of chemosaturation therapy,” said Eamonn P. Hobbs, president and chief executive officer of Delcath Systems. “Quintiles brings a compelling combination of scientific and medical knowledge, as well as broad experience in the European oncology marketplace that will help to support our own sales and marketing efforts.”

Chris Pepler, Quintiles’ head of Commercial Services in Europe, Middle East and Africa, said, “The complexities in the European health care market can pose significant operational and market-place risk for companies based internationally and looking to launch here. Successfully navigating local health care systems requires deep local knowledge and expertise. We’re drawing on this local experience, alongside our consistent global standards of quality and delivery to provide comprehensive commercial solutions as Delcath launches their product in multiple markets across Europe.”